Development of a novel observer-reported outcome measure for the assessment of Respiratory Syncytial Virus (RSV) infection symptoms in pediatric clinical trials

Abstract Background Respiratory syncytial virus (RSV) is a seasonal infection affecting most children by 2 years of age and the leading cause of lower respiratory tract infection requiring hospitalization in infants. Novel antiviral medications are in development to improve the clinical outcomes of...

Full description

Saved in:
Bibliographic Details
Main Authors: Sandy Lewis (Author), Carla DeMuro (Author), Stan L. Block (Author), Shelly Senders (Author), Paul Wisman (Author), Seth Toback (Author), Jason W. Chien (Author), Valerie Williams (Author)
Format: Book
Published: SpringerOpen, 2018-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8dcb8cdb9c544022a54a2396aeabcb47
042 |a dc 
100 1 0 |a Sandy Lewis  |e author 
700 1 0 |a Carla DeMuro  |e author 
700 1 0 |a Stan L. Block  |e author 
700 1 0 |a Shelly Senders  |e author 
700 1 0 |a Paul Wisman  |e author 
700 1 0 |a Seth Toback  |e author 
700 1 0 |a Jason W. Chien  |e author 
700 1 0 |a Valerie Williams  |e author 
245 0 0 |a Development of a novel observer-reported outcome measure for the assessment of Respiratory Syncytial Virus (RSV) infection symptoms in pediatric clinical trials 
260 |b SpringerOpen,   |c 2018-02-01T00:00:00Z. 
500 |a 10.1186/s41687-018-0034-9 
500 |a 2509-8020 
520 |a Abstract Background Respiratory syncytial virus (RSV) is a seasonal infection affecting most children by 2 years of age and the leading cause of lower respiratory tract infection requiring hospitalization in infants. Novel antiviral medications are in development to improve the clinical outcomes of RSV; however, no clinical outcome assessments (COAs) for RSV have been developed in alignment with the United States Food and Drug Administration patient-reported outcome guidance to assist in the evaluation of new therapies. To address this need, an observer-reported outcome (ObsRO) measure designed to assess observable RSV symptoms was created. Methods The literature was reviewed to evaluate existing COAs and identify constructs of interest. Individual caregiver interviews elicited concepts that informed item development, and candidate items were subsequently evaluated in two rounds of cognitive testing. Separate cohorts of caregivers of RSV-infected nonhospitalized and hospitalized infants participated. Therapeutic-area experts provided input throughout the instrument development process. Results Caregivers of 39 children < 24 months old with RSV (31 nonhospitalized, 8 hospitalized) participated in in-depth, individual interviews during concept elicitation and cognitive debriefing, resulting in 21 concepts identified as potentially observable and relevant to young children with RSV. The item pool was reduced to 12 cardinal symptoms and behavior impacts reported to be directly observable by caregivers, with 10 daytime and 9 nighttime symptoms to capture diurnal variation in severity. Conclusions The RSV Caregiver Diary assesses RSV symptom severity and change from the parent or caregiver perspective in a standardized manner to measure treatment benefit. Following psychometric evaluation and refinement, this tool is expected to be suitable for assisting in the clinical development of RSV therapeutics. 
546 |a EN 
690 |a Respiratory syncytial virus 
690 |a Clinical outcomes assessment 
690 |a Observer-reported outcome 
690 |a Caregiver diary 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-9 (2018) 
787 0 |n http://link.springer.com/article/10.1186/s41687-018-0034-9 
787 0 |n https://doaj.org/toc/2509-8020 
856 4 1 |u https://doaj.org/article/8dcb8cdb9c544022a54a2396aeabcb47  |z Connect to this object online.